Table 3.
Number of patients, events, and event rate for the kidney outcome in patients with normoalbuminuria stratified by the fourth quartile of TNF receptor-1 or TNF receptor-2 and in patients with normoalbuminuria, microalbuminuria, and macroalbuminuria
| Subgroup | Cutoff Value | No. of Patients | No. of Events | Event Rate, per 1000 Patient-yr |
|---|---|---|---|---|
| TNFR-1<4th quartile + normoalbuminuria | <2992 pg/ml | 1915 | 31 | 2.80 (1.97 to 3.98) |
| TNFR-1≥4th quartile + normoalbuminuria | ≥2992 pg/ml | 638 | 20 | 5.57 (3.59 to 8.63) |
| TNFR-2<4th quartile + normoalbuminuria | <11,394 pg/ml | 1915 | 26 | 2.35 (1.60 to 3.45) |
| TNFR-2≥4th quartile + normoalbuminuria | ≥11,394 pg/ml | 638 | 25 | 6.98 (4.72 to 10.33) |
| Normoalbuminuriaa | <30 mg/g | 2553 | 51 | 3.48 (2.64 to 4.58) |
| Microalbuminuria | <300 mg/g | 778 | 45 | 10.49 (7.83 to 14.05) |
| Macroalbuminuria | ≥300 mg/g | 201 | 41 | 43.06 (31.71 to 58.48) |
TNFR-1, TNF receptor-1; TNFR-2, TNF receptor-2.
a
Event rate was 5.44 (95% confidence interval, 3.70 to 7.99) per 1000 patient-years in the placebo group and 2.53 (95% confidence interval, 1.71 to 3.75) per 1000 patient-years in the canagliflozin group.